Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA).



Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later.



Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77-10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14-12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23-8.54).



HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV.
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Helen A
HA
Kelly
INSERM U1058 and University Hospital (CHRU), Montpellier, France.
Jean
J
Ngou
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Admire
A
Chikandiwa
Centre de Recherches Internationales en Santé, University of Ouagadougou, Ouagadougou, Burkina Faso.
Bernard
B
Sawadogo
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Clare
C
Gilham
National Health Laboratory Services, Johannesburg, South Africa.
Tanvier
T
Omar
Centre de Recherches Internationales en Santé, University of Ouagadougou, Ouagadougou, Burkina Faso.
Olga
O
Lompo
INSERM U1058 and University Hospital (CHRU), Montpellier, France.
Sylviane
S
Doutre
Centre de Recherches Internationales en Santé, University of Ouagadougou, Ouagadougou, Burkina Faso.
Nicolas
N
Meda
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.|MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Helen A
HA
Weiss
National Health Laboratory Services, Johannesburg, South Africa.
Sinead
S
Delany-Moretlwe
INSERM U1058 and University Hospital (CHRU), Montpellier, France.
Michel
M
Segondy
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.|Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
Philippe
P
Mayaud
D000328:Adult; D001706:Biopsy; D002050:Burkina Faso / Q000453:epidemiology; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000150:complications* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use; D015995:Prevalence; D011446:Prospective Studies; D013019:South Africa / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000473:pathology
D053918:Papillomavirus Vaccines